LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
608 IndexGastrostomy tube placement, 491,
495
GBM.SeeGlioblastoma multiforme
(GBM)
GCB.SeeGerminal center B cell
(GCB)
Gefitinib, 15, 212
Gemcitabine, 95, 100
based chemotherapy, for
pancreatic cancer, 245, 250
usage of, 87, 92
Gemtuzumab ozogamicin, 448
Gene expression profiling (GEP),
417, 431
Genetic susceptibility and second
cancers, 60, 65–66
Genetic testing, 583, 586
Genistein, effect of, 68
Genome-wide association studies
(GWAS), 72, 76
Genotoxic carcinogens, interaction
of, 57, 63
Genotypic markers, 71, 75
GEP.SeeGene expression profiling
(GEP)
German Hodgkin Study Group
(GHSG), 423, 434
Germ cell cancer, primary induction
chemotherapy in, 95, 100
Germ cell tumors, 298, 402, 411,
412, 510, 513
BEP in, 298, 299, 302, 303
HIV infection and, 298, 301
low risk, 402, 412
ovarian cancer and, 309, 313
risk factor for, 298
treatment of, 298, 302
varieties of, 402, 411–412
VIP, 299, 303
Germinal center B cell (GCB), 417,
431
Gestational choriocarcinoma,
metastatic, 481
Gestational trophoblastic disease
(GTD), 315
haploid paternal genome and, 315
p53 mutation in, 315
Gestational trophoblastic neoplasia
(GTN), 321, 329
actinomycin-D and, 330
methotrexate in, 322, 330
treatment for, 322, 330
GHSG.SeeGerman Hodgkin Study
Group (GHSG)
GI.SeeGastrointestinal (GI)
Giant cell tumor (GCT), 368, 373
Ginkgo, effects of, 590, 594
GIST.SeeGastrointestinal stromal
tumor (GIST)Glioblastoma multiforme (GBM),
391
gene mutation in, 384, 388
primary (de novo), 383, 388
recurrence of, bevacizumab for,
385, 390
standard radiation therapy for,
390
Glucagonoma, 518, 522
Glutathione-S-transferases, 43
GM-CSF.See
Granulocyte-macrophage
colony-stimulating factor
(GM-CSF)
GOG.SeeGynecologic Oncology
Group (GOG)
Gompertzian kinetics, 97, 101
Goserelin, 128
gp100, 106, 110
Grade 3 immune-mediated
enterocolitis, 378, 381–382
Graft failure, risk for, 528, 533
Graft-versus-host disease (GVHD),
453
acute
risk of, 527, 529, 533, 536
infection prophylaxis in chronic,
527, 533
Graft-versus-leukemia (GVL) effect,
107, 112
after transplant in chronic-phase
CML, 526, 532
allogeneic HSCT and, 525,
531
Graft-versus-tumor effect, 529,
535–536
Granular cell carcinoma, 288
Granulocyte colony-stimulating
factor (G-CSF), 21
primary prophylactic use of, 551,
556
Granulocyte-macrophage
colony-stimulating factor
(GM-CSF), 106, 111
Grapefruit juice, use of, 592,
595–596
G1/S, 2, 9
G1/S-phase transition, 17, 25
GTD.SeeGestational trophoblastic
disease (GTD)
GTN.SeeGestational trophoblastic
neoplasia (GTN)
GTP-binding proteins, 7, 15
classes of, 15
hydrolysis of, 16
GVHD.SeeGraft-versus-host
disease (GVHD)
GWAS.SeeGenome-wide
association studies (GWAS)Gynecologic Oncology Group
(GOG), 329HAART.SeeHighly active
antiretroviral therapy
(HAART)
Hair loss, systemic chemotherapy
and, 559
Halo sign, 541, 547
Hamartomatous polyps, 159–160
Hand-foot syndrome, 555, 559
Hashimoto’s thyroiditis, 215, 223
MALT and, 263, 267
Hayflick phenomenon, 5, 13
Hazard ratio (HR), 249, 250
HBV.SeeHepatitis B virus (HBV)
HCC.SeeHepatocellular
carcinoma (HCC)
hCG.SeeHuman chorionic
gonadotropin (hCG)
HCV.SeeHepatitis C virus (HCV)
HDGC.SeeHereditary diffuse
gastric cancer (HDGC)
Health care
cost of, 117, 120
quality care of, 116, 119
Health-related quality of life
(HRQOL), 117, 120
Health services research, difficulties
in, 115, 119
Helicobacter pylori,54
Hematopoietic stem cell
transplantation (HSCT), 460,
462
Hemochromatosis and HCC, 253,
257
Hemorrhagic cystitis, 125, 131
causes of, 125
prevention of, 526, 532
Hepatic toxicity, herbal
supplements with, 591, 595
Hepatic tumor embolization, 165,
175
Hepatitis B virus (HBV), 39, 50,
106, 111, 252
characteristics of, 39, 50–51
HCV and, 256, 260
Hepatitis C virus (HCV), 38, 50,
106, 111
causes of, 50
HBV infection and, 256, 260
HCC and, 38, 39, 50
Hepatoblastoma, 255, 259–260,
401, 410–411
Beckwith-Wiedemann syndrome
and, 401, 411
incidence of, 255, 259–260
staging workup for, 401, 411
treatment of, 259–260, 401, 411